Amarin CorpAMRN
About: Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
Employees: 275
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
281% more call options, than puts
Call options by funds: $392K | Put options by funds: $103K
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
3.62% less ownership
Funds ownership: 19.56% [Q2] → 15.94% (-3.62%) [Q3]
7% less funds holding
Funds holding: 169 [Q2] → 157 (-12) [Q3]
26% less capital invested
Capital invested by funds: $55.3M [Q2] → $41.1M (-$14.2M) [Q3]
41% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 29
43% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 44
Research analyst outlook
We haven’t received any recent analyst ratings for AMRN.
Financial journalist opinion
Based on 3 articles about AMRN published over the past 30 days